secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001390478-24-000011
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS Q1 net loss $9.6M; Phase 2 SLS009 100% response in ASXL1 AML; IDMC backs REGAL trial
--------------------------------------------------------------------------------

- Net loss of $9.6M ($0.21/share) vs $11.1M ($0.47/share) in Q1 2023.
- Cash and equivalents $18.4M at March 31, 2024; R&D expense $5.1M, G&A $4.5M.
- IDMC recommends continue Phase 3 REGAL (GPS in AML) without modification; next review June 2024 of all 127 patients.
- SLS009 Phase 2: 62% anti-leukemic activity all doses, 67% at 30mg BIW; 100% ORR in ASXL1 mutation patients at 30mg BIW; cohort expanding.
- Phase 3 REGAL enrollment completed; provisional patent filed for SLS009 in ASXL1-mutated AML.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000139047824000011/0001390478-24-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000139047824000011/sls-20240514.htm
  HTML page:      https://secwatch.observer/filing/0001390478-24-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer